Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

Cohesin-Tx

Financiado

Cerrado

Cohesin Therapeutics. Precision medicine for treating STAG2 mutated cancers

The cohesin gene STAG2 has emerged as a new tumour suppressor frequently mutated in bladder cancer, Ewing sarcoma and acute myeloid leukaemia (AML). Currently, these cancers are treated by cytotoxic therapies and surgery. These tr... ver más

31/05/2024

FORSCHUNGSINSTITUT...

Presupuesto desconocido

Líder del proyecto

FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

FORSCHUNGSINSTITUT FUR MOLEK...

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2022-06-01
Fecha Fin: 2024-05-31

Líder del proyecto

FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The cohesin gene STAG2 has emerged as a new tumour suppressor frequently mutated in bladder cancer, Ewing sarcoma and acute myeloid leukaemia (AML). Currently, these cancers are treated by cytotoxic therapies and surgery. These treatment plans are limited by unwanted side effects, have not been able to eliminate the high mortality caused by AML, and have not improved over the last few decades. STAG2 mutations are therefore a biomarker for cancer patients with high medical need. We discovered that STAG2 mutated cancer cells are highly vulnerable to the inactivation of another protein, called STAG1, while healthy cells remain unaffected. This highly selective sensitivity of cancer cells towards such a treatment is exceptional and could be exploited for precision medicine. Our long-term aim is therefore to develop STAG1 inhibitors. This precision medicine would greatly decrease side effects and costs, from which patients, doctors, and health insurance companies would benefit. To enable the development of such a STAG1 inhibitor, exploring the innovation potential is essential. For this, several “stepping stones” need to be reached which we would like to achieve with support of this ERC-PoC grant: (1) optimising our building blocks for a STAG1 inhibitor (2) developing an intellectual property strategy, (3) assessing commercial feasibility and (4) developing a business plan. Altogether, this will result in a proposition package that can be used to present the commercial potential to strategic partners. For this purpose, we have assembled a team that shares the same enthusiasm to achieve our common goal: to develop precision medicine for patients suffering from STAG2 mutated cancer.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores